Innovate UK grants funds for breast cancer therapy project
12 Feb 2024
ImmunotherapyClinical Study
Preview
Source: Pharmaceutical Technology
The project involves the Institute of Cancer ResearchCancer Research, Durham University, the Royal Marsden Hospital and techbio company Concr. Credit: Dr Rebecca Marlow / ICR.
Innovate UK has awarded a £1m ($1.26m) grant for a collaborative initiative called AI-VISION to aid treatment decisions for breast cancer patients.
The project involves the Institute of Cancer Research (ICR)Cancer Research (ICR), Durham University, the Royal Marsden Hospital and techbio company Concr.
It will support clinical decision-making, including directing breast cancer patients on the use of immunotherapy.
AI-VISION is a 24-month observational clinical study to assess tissue samples from early triple-negative breast cancer (TNBC) patients.
These subjects will be analysed to define and establish chemotherapy response biomarkers, irrespective of immunotherapy status.
See Also:FDA grants breakthrough status to J&J’s nipocalimab for HDFN
Preview
Source: Pharmaceutical Technology
Hemogenyx gets reprieve as FDA lifts clinical hold on AML CAR-T therapy
Preview
Source: Pharmaceutical Technology
The study aims to validate the safety and performance of new computational methods to offer precision therapies for patients.
Concr will apply Bayesian computational frameworks, inspired by astrophysics, to interconnect diverse oncology data, enabling researchers to detect and develop biomarkers indicative of drug response.
The ICR will contribute genomic data from its genomics facility, which will be integrated with clinical findings from TNBC samples through Concr’s FarrSight platform.
The current TNBC treatment protocol typically involves physicians making treatment choices based on clinical and pathology findings.
However, despite significant strides in molecular genomic profiling, no licensed platform presently exists that links tumour molecular data with drug response predictions for TNBC.
The AI-VISION study seeks to fill this gap and enhance precision therapy.
Institute of Cancer Research London clinician-scientist and Royal Marsden clinical oncologist and project lead Dr Navita Somaiah stated: “It’s exciting to announce our new partnership, which is bringing together experts in cancer, genomics, astrophysics and artificial intelligence for an innovative project that is seeking to improve treatment for triple-negative breast cancer.
“The aim of our project is to uncover new potential ways to treat triple-negative breast cancer more effectively, by combining data from a variety of different sources and analysing it using AI. For example, we hope to uncover genomic characteristics that indicate sensitivity to immunotherapy, and could guide us to selecting the patients most likely to benefit from these newer therapies.”
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Targets
-Drugs
Hot reports
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.